Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study)
- 2 January 2014
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 164 (6) , 834-840
Abstract
Summary: ‘Multifocal bone lymphoma’ or ‘polyostotic lymphoma’ is a neoplasm with exclusive multifocal involvement of the skeleton, without affecting lymph nodes or other soft tissues. Knowledge on this uncommon condition is limited because the related literature is sparse and fragmentary. We reviewed cases of multifocal bone diffuse large B‐cell lymphoma (MB‐DLBCL) registered in a clinico‐pathological database of the International Extranodal Lymphoma Study Group that includes 499 cases of bone lymphoma. Clinical features, management and prognosis of 37 MB‐DLBCL patients and 63 ‘controls’ (stage‐IV DLBCL and skeletal involvement) were analysed. Presentation and treatment of MB‐DLBCL and controls were identical. At a median follow‐up of 52 months (10–189), MB‐DLBCL patients exhibited a significantly better response rate (92% vs. 65%; P = 0·002), progression‐free survival (5‐year: 56 ± 9% vs. 34 ± 6%; P = 0·003) and overall survival (5‐year: 74 ± 8% vs. 36 ± 7%; P = 0·002). Among MB‐DLBCL patients, the use of post‐chemo radiotherapy was associated with better overall survival (5‐year: 83 ± 12% vs. 55 ± 16%; P = 0·003). Two MB‐DLBCL patients (5·4%) with spine and skull involvement experienced central nervous system (CNS) relapse. Thus, MB‐DLBCL patients exhibit a significantly better prognosis compared to patients with advanced‐stage DLBCL, and should be treated with conventional anthracycline‐based chemotherapy, keeping intensified treatment for relapsing cases, considering involved‐field radiotherapy, and CNS prophylaxis in high‐risk patients.Keywords
This publication has 21 references indexed in Scilit:
- Early-Stage Primary Bone Lymphoma: A Retrospective, Multicenter Rare Cancer Network (RCN) StudyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Primary diffuse large B-cell lymphomas of the bone: prognostic relevance of protein expression and clinical factorsHuman Pathology, 2008
- Primary bone lymphoma: Treatment results and prognostic factors with long‐term follow‐up of 82 patientsCancer, 2006
- The evolving classification of soft tissue tumours: an update based on the new WHO classificationHistopathology, 2005
- Dramatical improvement of chemoresistant bone lymphoma with rituximabClinical Rheumatology, 2005
- State-of-the-Art Therapeutics: Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2005
- Malignant lymphoma of boneArchives of orthopaedic and trauma surgery, 2001
- Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patientsAnnals of Oncology, 2000
- Primary non-Hodgkin’s lymphoma of bone: a clinicopathological investigation of 60 casesLeukemia, 1999
- Osteolymphoma (primary bone lymphoma): an Australian review of 70 casesAustralian and New Zealand Journal of Medicine, 1999